Praful Ravi, Medical Oncologist at the Dana-Farber Lank Center for Genitourinary Oncology, shared a post on X about a recent paper by him and colleagues published in European Urology Oncology:
“Can oligometastatic prostate cancer be cured with ‘total therapy’? Check out our paper reporting on outcomes after fixed-duration ADT +/- ARPI, met-directed therapy and local therapy (if de novo) for omHSPC, published in European Urology Oncology.
At a median of 3 years after completing a median of 2 years of systemic therapy, 45% of patients remained progression free and off therapy. Median time to resume therapy was 4 years. Hint at potential durable long-term remission (and possible cure) with this approach.
Supports ongoing deintensification trials in selected mHSPC patients who achieve an excellent response to therapy, and future trials need to explore fixed-duration therapy in this space.”
Authors: Praful Ravi, Caiwei Zhong, Wanling Xie, Mai Anh Huynh, Atish Choudhury et al.
For more posts like this visit oncodaily.com.
Praful Ravi is a Genitourinary Medical Oncologist at the Dana-Farber Lank Center for Genitourinary Oncology and an Assistant Professor of Medicine at Harvard Medical School. His clinical work and research focus on prostate cancer, particularly in areas such as neoadjuvant therapy for high-risk prostate cancer, radioligand therapy, theranostics, and the development of endpoints and outcomes for clinical trials.